ArticleAAPS PharmSciTech2026
Rapid Identification of Counterfeit Biopharmaceuticals using Portable Fourier Transform Infrared Spectroscopy.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biopharmaceuticals are expensive due to their sophisticated manufacturing processes, challenges in analytical characterization, and stringent storage and transportation conditions. Due to the high cost and increasing demand, they have emerged as a desirable target for counterfeiters. Challenges in the identification of counterfeits originate from the fact that biological products are extremely complex, requiring complex analytical tools and tedious sample preparations. These sophisticated techniques and operational expertise are not available in all regions of low-income nations, hence exacerbating the incidence of counterfeit pharmaceuticals. This study proposes a simple FTIR spectroscopy method to rapidly identify counterfeits from original biopharmaceuticals. The dataset comprises curated FTIR spectra from 43 monoclonal antibodies(mAbs) and 42 non-mAb products., pre-processed for noise reduction and baseline correction. The study was structured into three case studies: (1) Assessing biosimilarity, (2) Detection of counterfeits, and (3) Detection of products with compromised potency. The proposed method reliably identified deviations in both mAbs and non-mAb therapeutics. Biosimilars that were outliers in PCA score plots were flagged as counterfeits across multiple analytical approaches, and mAbs diluted to 70% concentration were effectively distinguished using PCA and K-means clustering. Counterfeit detection was validated by RP-HPLC analysis. This integrated pipeline offers a rapid, label-free, and non-destructive solution for ensuring product integrity in biopharmaceutical manufacturing and distribution. These findings underscore that Fourier-Transform Infrared (FTIR) spectroscopy, paired with statistical and machine learning approaches, can be used for rapid, easy, real-world counterfeit detection and quality assurance of biopharmaceuticals.
Indexed as
Identifiers
42265385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.